Kairos Pharma Makes Big Move with Initial Public Offering
Kairos Pharma, Ltd. has taken a notable step in the biopharmaceutical field by successfully completing its initial public offering (IPO). This clinical-stage company, focused on the development of groundbreaking cancer therapies, raised $6.2 million by offering 1,550,000 shares priced at $4.00 each. Now, their common stock is trading on the NYSE American LLC under the ticker symbol KAPA.
Investing IPO Proceeds in Future Trials
The funds raised from the IPO are vital for advancing the company's clinical trials. Specifically, they will help fund a Phase 1 trial targeting lung cancer, along with a Phase 2 trial for prostate cancer, using Kairos Pharma's leading candidate, ENV 105. This drug is designed to tackle drug resistance in cancer treatments, aiming to improve patient care significantly.
Progressing Innovative Drug Development
Beyond financing these clinical trials, the IPO will also enable further progress on preclinical drug candidates. Among these is KROS 101, a small molecule agonist aimed at targeting the GITR ligand, which shows promise in enhancing T cell activity against cancer cells. This cutting-edge approach highlights Kairos Pharma's dedication to innovating cancer treatments, positioning it as a noteworthy company in the field.
Strong Underwriting Support
Boustead Securities, LLC served as the lead managing underwriter for this IPO, supported by co-managing underwriters EF Hutton LLC and Sutter Securities, Inc. With such a robust underwriting team backing this financing effort, Kairos Pharma is poised for significant advances in its upcoming research initiatives.
Legal Oversight and Registration
Dorsey & Whitney LLP provided legal counsel to Kairos Pharma, ensuring adherence to federal regulations. The Securities and Exchange Commission declared the registration statement on Form S-1 effective just before the share offerings commenced.
About Kairos Pharma
Based in Los Angeles, Kairos Pharma stands at the forefront of cancer treatment innovation. By concentrating on therapies that address drug resistance and activate the immune system, the company is paving the way for transformative advancements in oncology. Their dedicated research efforts aim to create solutions that significantly improve patient outcomes in cancer care.
Frequently Asked Questions
What type of company is Kairos Pharma?
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics.
How much money did Kairos Pharma raise in its IPO?
In its initial public offering, Kairos Pharma raised approximately $6.2 million.
What will the proceeds from the IPO be used for?
The proceeds will support clinical trials for lung and prostate cancer and advance preclinical drug candidates.
On which exchange is Kairos Pharma's stock traded?
Kairos Pharma's stock trades on the NYSE American LLC under the ticker symbol KAPA.
Who acted as the underwriter for the IPO?
Boustead Securities, LLC served as the lead managing underwriter, with additional support from EF Hutton LLC and Sutter Securities, Inc.
